GSKGLAXF 75 EBITDA per Share is $3.45 as of Mar. 2026. GuruFocus rates GLAXF with a GF Score™ of 75/100 and a GF Value™ of $21.80 (Modestly Overvalued). The stock has 1 warning sign investors should review. Among 815 Drug Manufacturers companies, GSK ranks worse than 54.36% on this metric.
GSK's EBITDA per Share for the
three
months ended in Mar. 2026 was $0.91.
Its EBITDA per Share for the trailing twelve months (TTM) ended in Mar. 2026 was $3.45.
During the past 12 months, the average EBITDA per Share Growth Rate of GSK was 37.70% per year.
During the past 3 years, the average EBITDA per Share Growth Rate was 6.30% per year.
During the past 5 years, the average EBITDA per Share Growth Rate was 3.60% per year.
During the past 10 years, the average EBITDA per Share Growth Rate was 0.90% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBITDA per Share growth rate using EBITDA per Share data.
The historical rank and industry rank for GSK's EBITDA per Share or its related term are showing as below:
GLAXF'
s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -41.4 Med: 5.7 Max: 96.1
Current: 6.3
During the past 13 years, the highest 3-Year average EBITDA per Share Growth Rate of GSK was 96.10% per year. The lowest was -41.40% per year. And the median was 5.70% per year.
GLAXF's 3-Year EBITDA Growth Rate is ranked worse than 54.36% of 815
companies
in the Drug Manufacturers industry
Industry Median: 8.9
vs GLAXF: 6.30
GSK's EBITDA for the
three
months ended in Mar. 2026 was $3,699 Mil.
During the past 12 months, the average EBITDA Growth Rate of GSK was 36.40% per year.
During the past 3 years, the average EBITDA Growth Rate was 6.50% per year.
During the past 5 years, the average EBITDA Growth Rate was 4.10% per year.
During the past 10 years, the average EBITDA Growth Rate was 1.50% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBITDA Growth Rate using EBITDA data.
During the past 13 years, the highest 3-Year average EBITDA Growth Rate of GSK was 90.30% per year. The lowest was -42.10% per year. And the median was 6.60% per year.
GSK (OTCPK:GLAXF) EBITDA per Share Explanation
EBITDA is a cash flow measure that ignores changes in working capital. EBITDA minus Depreciation, and Amortization (DA) equals EBIT. EBIT is profit before interest and taxes. Of course, Interest and taxes need to be paid.
While depreciation and amortization expenses do not need to be paid in cash, assets - especially tangible assets - do need to be replaced over time. EBITDA is not a measure of profit in any sense. EBITDA is a measure of cash generation by a business where the uses of that cash may be more or less discretionary depending on the nature of the business.
The EBITDA of a TV station is largely discretionary. Owners may use much of the EBITDA generated by a TV station as they see fit. The EBITDA of a railroad is largely non-discretionary. Owners must use much of the EBITDA generated by a railroad to replace the physical assets of the railroad or the business will literally fall apart over time.
EBITDA can be thought of as the cash a business generates that is available to:
Add more inventory
Add more receivables
Replace property, plant, and equipment
Add more property, plant, and equipment
Pay interest
Pay taxes
And finally: pay owners
EBITDA is widely used in financial analysis because Depreciation and Amortization are not present day cash expenses. Depreciation and amortization are the spreading out of the costs of assets over the time in which those assets provide benefits. Today's depreciation and amortization expenses relate to assets bought in the past. The assets being expensed may or may not need to be replaced in the future. And the cost to replace the assets may be more or less than it was in the past. For this reason, the depreciation and amortization expenses a company records in the present year may have no relationship to the actual cash costs needed to maintain its assets in future years.
A company's depreciation expense depends on both its expectations about the assets it owns and its choice of accounting methods. Two companies owning identical assets may have different depreciation expenses because they have different expectations about the useful lives of those assets and because they make different accounting choices.
Analysts use EBITDA to remove this element of personal choice from a company's accounting statements. The use of EBITDA is an attempt to make the results of different companies more comparable and uniform.
Be Aware
Although depreciation is not a cash cost, it is a real business cost because the company has to pay for the fixed assets when they purchase them. Both Warren Buffett and Charlie Munger hate the idea of EBITDA because in this calculation, depreciation is not counted as an expense.
EBITDA over Revenue is a good metric for comparing the operating efficiencies between companies because EBITDA is less vulnerable to companies' accounting choices. For this reason, EBITDA is used in ranking the Predictability of Companies.
GSK EBITDA per Share Related Terms
GSK EBITDA per Share Historical Data
* Premium members only.
The historical data trend for GSK's EBITDA per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
GSK's EBITDA per Share for the fiscal year that ended in Dec. 2025 is calculated as
EBITDA per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $3.45
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
GSK (GLAXF) has a EBITDA per Share of $3.45 as of Mar. 2026. EBITDA per share is the per-share amount of earnings before interest, taxes, depreciation and amortization. View historical data on GSK and its competitors. According to the industry distribution chart, GSK ranks #443 out of 815 companies in the Drug Manufacturers industry, placing it in the top 54.4%.
Is GSK's EBITDA per Share too high?
GSK's current EBITDA per Share is $3.45. The Drug Manufacturers industry median EBITDA per Share is 8.90. GSK's value of $3.45 is 61.2% below this industry median. Based on the distribution chart, GSK ranks #443 out of 815 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, GSK has a GF Score™ of 75/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does GSK's EBITDA per Share compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, GSK ranks #443 out of 815 companies for EBITDA per Share. This places GSK in the lower half of its industry. The industry median EBITDA per Share is 8.90. GSK's value of $3.45 is 61.2% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA per Share for a Drug Manufacturers company?
The median EBITDA per Share among Drug Manufacturers companies is 8.90, based on 815 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA per Share significantly above this median, while those in the bottom quartile fall well below. However, EBITDA per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. GSK's current EBITDA per Share of $3.45 is 61.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA per Share mean?
A high EBITDA per Share can signal that a stock is expensive relative to its fundamentals. EBITDA per share is the per-share amount of earnings before interest, taxes, depreciation and amortization. View historical data on GSK and its competitors. For the Drug Manufacturers industry, the median EBITDA per Share is 8.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. GSK's current EBITDA per Share is $3.45. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is GSK stock overvalued right now?
Based on GuruFocus' analysis, GSK (GLAXF) is currently considered Modestly Overvalued. The stock's GF Value™ is $21.80, compared to a current price of $25.33 — trading 16.2% above its estimated fair value. The current EBITDA per Share is $3.45 and 61.2% below the Drug Manufacturers industry median of 8.90. GSK's overall GF Score™ is 75/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA per Share calculated?
EBITDA per Share is calculated from a company's financial statements. For GSK (GLAXF), the current EBITDA per Share is $3.45 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is GSK (GLAXF) Overvalued in 2026?
Based on GuruFocus' analysis, GSK stock appears to be overvalued.
The current stock price of $25.33 is trading 16.2% above its estimated GF Value™ of $21.80.
GuruFocus considers GSK to be Modestly Overvalued.
Key valuation signals for GLAXF:
EBITDA per Share: $3.45
GF Value™: $21.80 vs. price of $25.33 (16.2% above fair value)
Industry Position: 61.2% below the Drug Manufacturers median (#443 of 815)
No single metric tells the full story. See the GLAXF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, antiviral, and vaccines, and has been growing its presence in oncology and immunology, as well. GSK uses joint ventures to gain additional scale in certain markets like HIV.
75GF Score
Get the complete analysis for GLAXF
EBITDA per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
GLAXF has been successfully added to your 
